Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Co.'s research is focused in the areas of inflammation and immunology. Co.'s program includes: YUPELRI (revefenacin) inhalation solution, a nebulized long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease: and Gut-selective Pan-Janus kinase inhibitor program (TD-1473), which is in development as a potential treatment for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. The TBPH stock yearly return is shown above.
The yearly return on the TBPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TBPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|